73
- O’Donnell MT, Greer LT, Nelson J, Shriver C, Vertrees A (2014) Diversion remains the stan-
dard of care for modern management of war-related rectal injuries. Mil Med 179:778–782 - Kessinger A (1998) Consensus conference on high-dose therapy with hematopoietic stem cell
transplantation in diffuse large-cell lymphoma. Type of cells, optimal mobilization of stem
cells – positive and negative selection. Ann Oncol 9(Suppl 1):S23–S30 - Masip J, Vecilla F, Paez J (1998) Diffuse pulmonary hemorrhage after fibrinolytic therapy for
acute myocardial infarction. Int J Cardiol 63:95–97 - McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M et al (1988) The SCID-hu
mouse: murine model for the analysis of human hematolymphoid differentiation and func-
tion. Science 241:1632–1639 - Fujiwara S, Matsuda G, Imadome K (2013) Humanized mouse models of epstein-barr virus
infection and associated diseases. Pathogens 2:153–176 - Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M et al (2002) NOD/SCID/gamma(c)
(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood
100:3175–3182 - Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC et al (2004) Development of a
human adaptive immune system in cord blood cell-transplanted mice. Science 304:104–107 - Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T et al (2005) Development of func-
tional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null)
mice. Blood 106:1565–1573 - Ma SD, Xu X, Jones R, Delecluse HJ, Zumwalde NA et al (2016) PD-1/CTLA-4 blockade
inhibits Epstein-Barr virus-induced lymphoma growth in a cord blood humanized-mouse
model. PLoS Pathog 12:e1005642 - Shultz LD, Saito Y, Najima Y, Tanaka S, Ochi T et al (2010) Generation of functional human
T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/
IL2r gamma (null) humanized mice. Proc Natl Acad Sci U S A 107:13022–13027 - Chijioke O, Muller A, Feederle R, Barros MH, Krieg C et al (2013) Human natural killer
cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infec-
tion. Cell Rep 5:1489–1498 - Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D et al (2011) A new model of Epstein-Barr
virus infection reveals an important role for early lytic viral protein expression in the develop-
ment of lymphomas. J Virol 85:165–177 - Ma SD, Xu X, Plowshay J, Ranheim EA, Burlingham WJ et al (2015) LMP1-deficient
Epstein-Barr virus mutant requires T cells for lymphomagenesis. J Clin Invest 125:304–315 - Minamitani T, Ma Y, Zhou H, Kida H, Tsai CY et al (2017) Mouse model of Epstein-Barr
virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease. Proc
Natl Acad Sci U S A 114:4751–4756 - Camicia R, Winkler HC, Hassa PO (2015) Novel drug targets for personalized precision
medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol
Cancer 14:207 - Perry AR, Goldstone AH (1998) High-dose therapy for diffuse large-cell lymphoma in first
remission. Ann Oncol 9(Suppl 1):S9–14 - Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM et al (1993) Comparison of a
standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-
Hodgkin’s lymphoma. N Engl J Med 328:1002–1006 - Friedberg JW, Fisher RI (2008) Diffuse large B-cell lymphoma. Hematol Oncol Clin North
Am 22(941–952):ix - Raut LS, Chakrabarti PP (2014) Management of relapsed-refractory diffuse large B cell lym-
phoma. South Asian J Cancer 3:66–70 - Zinzani PL, Pellegrini C, Argnani L, Broccoli A (2016) Prolonged disease-free survival in
elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus ritux-
imab. Haematologica 101:e385–e386 - Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R et al (2005) Long-term
results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell
5 EBV-Associated B-Cell Lymphomas